GalNAc-L96 – A Key Molecule for Efficient RNA Targeted Delivery
Introduction to GalNAc-L96
GalNAc-L96 (CAS 1159408-62-4) is a triantennary N-acetylgalactosamine (GalNAc) ligand primarily used for the synthesis of GalNAc-siRNA. GalNAc is a specific ligand for ASGPR (Asialoglycoprotein Receptor), enabling liver-targeted delivery, which is a crucial aspect of modern RNA delivery technology.
Applications and Advantages of GalNAc-L96
- Precise Liver-Targeted Delivery: ASGPR is highly expressed on liver cell surfaces, allowing siRNA, antisense oligonucleotides (ASO), or other nucleic acid drugs conjugated with GalNAc-L96 to efficiently enter liver cells and enhance therapeutic effects.
- Enhanced Bioavailability of siRNA: Traditional siRNA delivery methods (such as lipid nanoparticles, LNPs) often lead to non-specific distribution, whereas GalNAc-conjugated siRNA (GalNAc-siRNA) enables more efficient and safer RNA interference (RNAi) therapy.
- Reduced Systemic Toxicity: Due to the high specificity of GalNAc delivery, compared to LNPs, GalNAc-siRNA exhibits lower immunogenicity and reduced side effects, making it a preferred strategy for RNA drug development.
- Improved Stability and Optimized Pharmacokinetics: By optimizing the structure of GalNAc-L96, its affinity for ASGPR can be enhanced, thereby increasing hepatic cell uptake and prolonging in vivo half-life.
Watson’s Unique Advantages in the GalNAc Field
- Advanced Synthesis Techniques and Purity Control
- Watson leverages cutting-edge glycochemistry and nucleic acid modification technologies to provide high-purity, high-quality GalNAc-L96 and its derivatives, ensuring optimal outcomes in RNAi and ASO drug development.
- Comprehensive Support from Lab to Industrial Scale
- Watson not only supplies small-scale research-grade products but also has pilot and industrial-scale production capabilities, meeting the demands from early-stage research to clinical production.
- Strict adherence to quality management systems (ISO certification) ensures product quality and stability.
- Strong Technical Expertise and Industry Recognition
- With years of experience in glycoconjugates and RNA delivery, Watson collaborates with leading pharmaceutical and biotechnology companies worldwide, driving advancements in RNA therapeutics.
- Watson’s high-end customization and innovative synthesis capabilities make it a key global partner in RNA delivery technologies.
Conclusion
As a core ligand for RNA-targeted delivery, GalNAc-L96 plays a vital role in siRNA and ASO therapies. With cutting-edge synthesis technologies, strict quality control, and strong customization capabilities, Watson holds a distinct competitive advantage in this field, supporting breakthroughs in RNA delivery technology.
If you are interested in GalNAc-related products or RNA delivery solutions, feel free to contact Watson for more information!
Sales Link
GalNAc-L96 – A Key Molecule for Efficient RNA Targeted Delivery on Watson
